Lakefront Biotherapeutics NV (LKFT) News
Follow Lakefront Biotherapeutics NV (LKFT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Lakefront Biotherapeutics Nine-Month Revenue Drops 88% as Gilead Access Rights End
EARNINGS | Nov 11, 2026, 09:12 PM UTC
M
Lakefront Biotherapeutics Reports €13.9M Nine-Month Profit
Lakefront reported a €13.9 million net profit for the nine months of 2026, versus a €461.3 million net loss in 2025. Cash and financial investments totaled €2,183.1 million at September 30; year-end 2026 guidance is at l
EARNINGS | Nov 11, 2026, 09:02 PM UTC
M
Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics
MNA | Oct 14, 2026, 09:02 PM UTC
M
Lakefront Agreement Includes EUR8M Upfront Payment, Up to $230M in Milestones
The agreement includes an EUR8M upfront payment, potential milestone payments of up to $230M and a low-single-digit royalty to Lakefront.
EQUITY | Oct 14, 2026, 08:05 PM UTC
L
Lakefront Biotherapeutics NV (LKFT) Repurchases 106,060 Shares
Lakefront Biotherapeutics NV repurchased 106,060 shares between Sept 21—25, 2026, under its June 9 buyback program. It held 1,633,594 treasury shares as of Sept 25 market close.Material DetailsContext by AI AnalystThis i
EQUITY | Sep 29, 2026, 08:08 PM UTC
L
Acquisition of Own Shares
Mechelen, Belgium; 29 September 2026, 22.01 CET; regulated informationWithin the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announc
MNA | Sep 29, 2026, 08:08 PM UTC
H
Crude Oil Gains 1%; Cintas Earnings Top Views
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Wednesday. The Dow traded down 0.52% to 51,588.15 while the NASDAQ dipped 1.10% to 26,943.90. The S&P 500 also fell, drop
LIVE | Sep 23, 2026, 06:08 PM UTC
L
Lakefront Biotherapeutics Price Target Raised to $45.00/Share From $26.00 by RBC Capital
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 01:01 PM UTC
L
RBC Capital upgrades Lakefront Biotherapeutics to Outperform, sets $45 price target
RBC Capital upgraded Lakefront Biotherapeutics's stock to Outperform with a price target of $45.00.The price target implies an upside of 70.7% from the Sep 22 close of $26.36.Key takeaways from the analyst notePromising
EQUITY | Sep 23, 2026, 12:51 PM UTC
L
Lakefront Biotherapeutics repurchases 127,796 own shares under buyback
Lakefront Biotherapeutics NV says that between August 24, 2026 and August 28, 2026 it repurchased 127,796 own shares under its repurchase program announced June 9, 2026.
MNA | Sep 01, 2026, 08:08 PM UTC
M
Lakefront Biotherapeutics Receives Transparency Notification As Madison Avenue Partners Crossed Above 5% Of Voting Rights
Lakefront Biotherapeutics NV ((Euronext &, NASDAQ: LKFT ) received a transparency notification from Madison Avenue Partners. Pursuant to Belgian transparency legislation1, Lakefront received a transparency notification f
MNA | Jun 29, 2026, 08:03 PM UTC